Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARRIVAL: Ivacaftor in infants with CF
NCT02725567Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2016
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Jun 2016; status: completed.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02725567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02725567.